title: Parry-Romberg syndrome vasculopathy and its treatment with botulinum toxin.
abstract: Parry-Romberg syndrome is a rare condition characterized by progressive, hemifacial atrophy, hair loss, enophthalmos, retinal vasculopathy occasionally associated with hemicranial pain syndrome (secondary trigeminal neuralgia). The cause of the condition is unknown; however, substantial evidence suggests that vasculopathy plays a significant role in the genesis of the neurologic damage and facial lipodystrophy. Herein describes a case of Parry-Romberg syndrome treated with repetitive botulinum type A toxin injections, with almost complete resolution of severe chronic pain.
authors.affiliation: *Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Quincy; †Cambridge, Quincy, Massachusetts; ‡Department of Neuroradiology, Massachusetts General Hospital, Boston, Massachusetts; and §Department of Anesthesia, Tufts University School of Medicine, Saint Elizabeth's Hospital, Brighton, Massachusetts, U.S.A.
authors.forename: Gary E
authors.initials: GE
authors.lastname: Borodic
authors.forename: Paul
authors.initials: P
authors.lastname: Caruso
authors.forename: Martin
authors.initials: M
authors.lastname: Acquadro
authors.forename: Sarah
authors.initials: S
authors.lastname: Chick
mesh_terms: D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D005150:Facial Hemiatrophy / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D013667:Technetium; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed
chemical_list: D009465:Neuromuscular Agents; D013667:Technetium; D019274:Botulinum Toxins, Type A